|Articles|April 14, 2020

Kayentis Forges Ahead on New eCOA Service Projects

Kayentis has announced it is forging ahead on five new eCOA service projects with Emerging BioPharma companies. The projects Kayentis is collaborating on involve phase II and III clinical studies in therapeutic areas addressing unmet needs in areas like oncology, immune disorders, and rare diseases. In response to COVID-19, Kayentis has implemented a dedicated contingency plan for sites and patients to keep trials running.

For more information, click here. 


Related to this article

© putilov_denis - © putilov_denis - stock.adobe.com
Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.